Server cans autism hope bumetanide after phase 3 fails

Servier and Neurochlore have been forced to admit defeat in their bid to bring the first drug to market for people with autism spectrum disorder (ASD), after a comprehensive fail for their

FDA grants swift approval to Cognoa's digital device for aut...

The FDA has approved a digital device developed by Cognoa that can be used to diagnose autism spectrum disorder (ASD), just a few weeks after it was filed for approval.

Cognoa preps FDA filing for digital autism diagnostic

An artificial intelligence-powered diagnostic for autism spectrum disorder (ASD), developed by Cognoa, has met all its objectives in a pivotal trial and will be filed for approval with the

Simple eye test could help screen kids for autism

Roche’s autism drug granted FDA ‘breakthrough’ status

A drug which could become the first ever treatment for Autism Spectrum Disorder has been granted Breakthrough Therapy Designation by the FDA.